About Adaptive Biotechnologies
Adaptive Biotechnologies is a company based in Seattle (United States) founded in 2009 by Harlan Robins and Chad Robins. Adaptive Biotechnologies has raised $419.15 million across 18 funding rounds from investors including Microsoft, Illumina and LabCorp. The company has 619 employees as of December 31, 2024. Adaptive Biotechnologies has completed 1 acquisition, including Sequenta. Adaptive Biotechnologies offers products and services including clonoSEQ, Adaptive Immunosequencing, and Pharma Services. Adaptive Biotechnologies operates in a competitive market with competitors including Moderna, Chimerix, HOOKIPA Pharma, Novavax and Generate Biomedicines, among others.
- Headquarter Seattle, United States
- Employees 619 as on 31 Dec, 2024
- Founders Harlan Robins, Chad Robins
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adaptive Biotechnologies Corporation
-
Annual Revenue
$178.96 M (USD)5.1as on Dec 31, 2024
-
Net Profit
-$159.49 M (USD)29.19as on Dec 31, 2024
-
EBITDA
-$134.08 M (USD)25.25as on Dec 31, 2024
-
Total Equity Funding
$419.15 M (USD)
in 18 rounds
-
Latest Funding Round
Not available
-
Investors
Microsoft
& 13 more
-
Employee Count
619
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Adaptive Biotechnologies
Adaptive Biotechnologies is a publicly listed company on the NASDAQ with ticker symbol ADPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Adaptive Biotechnologies
Adaptive Biotechnologies offers a comprehensive portfolio of products and services, including clonoSEQ, Adaptive Immunosequencing, and Pharma Services.
NGS-based tool for assessing minimal residual disease in trials.
Technology for mapping immune receptors in drug discovery.
Services supporting clinical diagnostics and therapeutic development.
People of Adaptive Biotechnologies
Unlock access to complete
Unlock access to complete
Software Development Team
62 people
Senior Team
36 people
Leadership Team
35 people
Operations Team
17 people
Sales and Marketing
16 people
Product Management Team
14 people
Research Team
12 people
Human Resources and Administration
11 people
Unlock access to complete
Funding Insights of Adaptive Biotechnologies
Adaptive Biotechnologies has successfully raised a total of $419.15M across 18 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Adaptive Biotechnologies
Adaptive Biotechnologies has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Microsoft, Illumina and LabCorp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked |
Investor details for Adaptive Biotechnologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adaptive Biotechnologies
Adaptive Biotechnologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Sequenta.
Investment portfolio details for Adaptive Biotechnologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Adaptive Biotechnologies
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Adaptive Biotechnologies
Detailed financials for Adaptive Biotechnologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adaptive Biotechnologies Comparisons
Peer comparison for Adaptive Biotechnologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Adaptive Biotechnologies
Adaptive Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Chimerix, HOOKIPA Pharma, Novavax and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Adaptive Biotechnologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adaptive Biotechnologies
Complete news archive for Adaptive Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adaptive Biotechnologies
Adaptive Biotechnologies was founded in 2009.
Adaptive Biotechnologies is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Chad Robins is the current CEO of Adaptive Biotechnologies. They have also founded this company.
Adaptive Biotechnologies is a funded company, having raised a total of $419.15M across 18 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Adaptive Biotechnologies is 619.
Annual revenue of Adaptive Biotechnologies is $178.96M as on Dec 31, 2024.
Adaptive Biotechnologies was founded in 2009 in Seattle, United States. Operations focus on the biotechnology sector, with services centered on immune disease diagnostics and drug discovery. The immunoSEQ sequencing technology is utilized to characterize the immune system, supporting scientific research and clinical development. clonoSEQ is employed for monitoring minimal residual disease in blood-based cancers. Cell therapies, vaccines, and antibody molecules are developed for infectious diseases.
Adaptive Biotechnologies's top competitors include Moderna, Generate Biomedicines and HOOKIPA Pharma.
Adaptive Biotechnologies offers clonoSEQ, Adaptive Immunosequencing, and Pharma Services.
Yes, Adaptive Biotechnologies is publicly traded on NASDAQ under the ticker symbol ADPT.
Adaptive Biotechnologies has made 1 acquisition, including Sequenta.
The ticker symbol of Adaptive Biotechnologies is ADPT on NASDAQ.